• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12B filed by Viela Bio, Inc.

    3/25/21 4:01:54 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care
    Get the next $VIE alert in real time by email
    15-12B 1 d127436d1512b.htm 15-12B 15-12B

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    001-39067

    (Commission File Number)

     

     

    VIELA BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

    One Medimmune Way, First Floor, Area Two

    Gaithersburg, Maryland

    (240) 558-0038

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

       ☒  

    Rule 12g-4(a)(2)

       ☐  

    Rule 12h-3(b)(1)(i)

       ☒  

    Rule 12h-3(b)(1)(ii)

       ☐  

    Rule 15d-6

       ☐  

    Rule 15d-22(b)

       ☐  

    Approximate number of holders of record as of the certification or notice date: One

     

     

     


    Pursuant to the requirements of the Securities Exchange Act of 1934, Viela Bio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: March 25, 2021     VIELA BIO, INC.
          By:  

    /s/ Paul W. Hoelscher

          Name:   Paul W. Hoelscher
          Title:  

    Executive Vice President, Chief Financial Officer

    Get the next $VIE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 5:13:43 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Tyrell Rivers

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:53:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Plc Astrazeneca

      4 - Viela Bio, Inc. (0001734517) (Issuer)

      3/16/21 8:52:55 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    SEC Filings

    See more
    • SEC Form 15-12B filed by Viela Bio, Inc.

      15-12B - Viela Bio, Inc. (0001734517) (Filer)

      3/25/21 4:01:54 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:15:53 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Viela Bio, Inc.

      S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

      3/15/21 9:12:58 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viela Bio, Inc.

      SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)

      3/17/21 7:40:24 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      3/10/21 9:46:40 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

      2/16/21 4:22:37 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

      GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve

      3/1/21 4:01:00 PM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

      -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur

      2/25/21 8:30:00 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $VIE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viela Bio downgraded by Guggenheim

      Guggenheim downgraded Viela Bio from Buy to Neutral

      2/8/21 11:51:17 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush

      Wedbush downgraded Viela Bio from Outperform to Neutral

      2/8/21 7:28:49 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care
    • Viela Bio downgraded by Wedbush with a new price target

      Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00

      2/8/21 7:26:43 AM ET
      $VIE
      Major Pharmaceuticals
      Health Care

    $VIE
    Leadership Updates

    Live Leadership Updates

    See more
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations